Covax and the rise of the ‘super public private partnership’ for global health
Bibliographic Data
| ID | 15541663 |
|---|---|
| Authors | Katerini T Storeng (0000-0003-0032-7006, London School of Hygiene & Tropical Medicine, corresponding author), Antoine de Bengy Puyvallée (0000-0002-5800-3701, University of Oslo), F Stein (0000-0002-0123-9895, University of Oslo) |
| Year | 2021 |
| Volume | 18 |
| Issue | 1 |
| Pages | 1987502-1987502 |
| Publication date | 2021-10-22 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Global Public Health (JOURNAL) |
| Journal identifiers | ISSN: 1744-1692 • E-ISSN: 1744-1706 |
| Publisher | Taylor & Francis (PUBLISHER • GB) |
| DOI | 10.1080/17441692.2021.1987502 |
| PMID | 34686103 |
| OpenAlex | W3207737652 |
| Language | EN |
| Citations received | 39 |
| References cited | 20 |
COVAX, the vaccines pillar of the Access to Covid-19 Tools Accelerator (ACT-A), has been promoted as 'the only global solution' to vaccine equity and ending the Covid-19 pandemic. ACT-A and COVAX build on the public-private partnership (PPP) model that dominates global health governance, but take it to a new level, constituting an experimental form that we call the 'super-PPP'. Based on an analysis of COVAX's governance structure and its difficulties in achieving its aims, we identify several features of the super-PPP model. First, it aims to coordinate the fragmented global health field by bringing together existing PPPs in an extraordinarily complex Russian Matryoshka doll-like structure. Second, it attempts to scale up a governance model designed for donor-dependent countries to tackle a health crisis affecting the entire world, pitting it against the self-interest of its wealthiest government partners. Third, the super-PPP's structural complexity obscures the vast differences between constituent partners, giving pharmaceutical corporations substantial power and making public representation, transparency, and accountability elusive. As a super-PPP, COVAX reproduces and amplifies challenges associated with the established PPPs it incorporates. COVAX's limited success has sparked a crisis of legitimacy for the voluntary, charity-based partnership model in global health, raising questions about its future
Accountability · Business · Civil society · Corporate governance · Equity (law · General partnership · Global governance · Global health · Health care · Legitimacy · Political science · Politics · Public health · Public–private partnership · Transparency (behavior · Global Health and Surgery · Global Maternal and Child Health · Global Public Health Policies and Epidemiology · Law · Medicine · Public Administration · Finance
‘Wisdom, solidarity and investment from within’
The role of global health partnerships in vaccine equity
The historic failure of the EU and nationalism in the Covid 19 pandemic
Covax and the many meanings of sharing
Accelerazione e governance della tecnoscienza
The radically unequal distribution of Covid-19 vaccinations
Web search behaviors and infodemic attitudes regarding Covid-19 in Turkey
Voluntariness or legal obligation? An ethical analysis of two instruments for fairer global access to Covid-19 vaccines
A critical review of Chinese vaccine enterprises in the global aid market
Participation pathways in global vaccine partnerships and their implications for immunization systems
A critical analysis of Covax alliance and corresponding global health governance and policy issues
Rethinking international financing for health to better respond to future pandemics
The World Economic Forum
Kan vi ha tillit til tilliten
Covid‐19 vaccine equity in doldrums
Public–Private Development Cooperation
Risky business
‘Our project, your problem?’ A case study of the WHO’s mRNA technology transfer programme in South Africa
Shared health governance, mutual collective accountability, and transparency in Covax
From PHEIC to PHECs
Challenges in international health financing and implications for the new pandemic fund
Covax, vaccine donations and the politics of global vaccine inequity
Which roads lead to access? A global landscape of six Covid-19 vaccine innovation models
Staring out my window
Responsible Accountability? Multi‐Stakeholder Partnerships, Sustainable Development and Global Health
Corporate Power in a Multistakeholder World
Can we move beyond vaccine apartheid? Examining the determinants of the Covid-19 vaccine gap
Blended finance to the rescue? Subsidies, vaccine bonds and matching funds in global health
Global Duties in Crisis Response
Covid-19 vaccine apartheid and the failure of global cooperation
Covid and structural cartelisation
Global inequities in access to Covid-19 health products and technologies
Quasi-public Partnerships
Beyond contact-tracing
Covid-19 Pandemic and Vaccine Imperialism
The World Health Organization and the Struggle to Coordinate Global Health Research
Vaccine diplomacy
From Imperialism to the “Golden Age” to the Great Lockdown
Can the Sick Speak? Global Health Governance and Health Subalternity
Governance Entrepreneurs
Gates's grandest challenge
Risky business
The Gavi Alliance and the ‘Gates approach’ to health system strengthening
Emerging Governance Architectures in Global Health
Loyal at once? The EU’s global health awakening in the Covid-19 pandemic
Civil society participation in global public private partnerships for health
The World Health Organization and the Transition From “International” to “Global” Public Health
Seven habits of highly effective global public-private health partnerships
| Unique citing works | 39 |
|---|---|
| Citations per year | 7,8 |
| Citation span | 2021 - 2026 (6) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 37 |